Hirudin protects against kidney damage in streptozotocin-induced diabetic nephropathy rats by inhibiting inflammation via P38 MAPK/NF-κB pathway
Mechanism study published in Drug Design, Development and Therapy (2020)
Abstract
BACKGROUND: Inflammation-induced podocyte apoptosis plays an important role in kidney injury during diabetic nephropathy (DN). Hirudin (HIR), a natural compound extracted from leeches, can inhibit inflammation. However, whether HIR can protect the kidneys against inflammation during DN is unknown. In the present study, we aimed to study the effects of HIR on kidney damage in a DN rat model and explore its anti-inflammatory properties. METHODS: A streptozotocin-induced DN rat model was generated, and HIR was administered subcutaneously. Immortal podocytes and primary peritoneal macrophages were used for vitro studies. Hematoxylin and eosin staining was used to evaluate renal pathological changes; quantitative polymerase chain reaction and immunoblotting were used to detect gene expression; and TUNEL staining was used to detect apoptotic cells. RESULTS: Our results showed that HIR protected against renal injury, as indicated by kidney weight/body weight, serum creatinine, renal pathological changes, blood urea nitrogen, and detection of urine proteins. Notably, HIR treatment reduced macrophage infiltration, pro-inflammatory cytokine expression, and podocyte apoptosis in the kidney tissues of DN rats. In vitro, high glucose (HG) induced the activation of M1 macrophages, which was accompanied by increased podocyte apoptosis. HIR could decrease HG-induced podocyte apoptosis and suppress pro-inflammatory cytokine expression in podocytes in vitro. This was achieved via inhibition of p38 MAPK/NF-κB activation in renal tissues and podocytes. CONCLUSION: HIR could inhibit inflammation via the p38 MAPK/NF-κB pathway, prevent podocyte apoptosis, and protect against kidney damage in a DN rat model.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Hirudin protects against renal damage in STZ-diabetic rats by inhibiting inflammation via P38 MAPK/NF-κB pathway — mechanistic basis for leech-hirudin anti-inflammatory action.
Warum dies für die Hirudotherapie relevant ist
Diese Studie untersuchte, ob Hirudin (HIR), eine aus Blutegeln extrahierte Substanz, in einem Streptozotocin-induzierten diabetische-Nephropathie(DN)-Rattenmodell durch Hemmung von Entzündung über den p38-MAPK/NF-κB-Signalweg vor Nierenschäden schützen kann. Hirudin reduzierte die Makrophageninfiltration, die Expression proinflammatorischer Zytokine und die Apoptose von Podozyten in DN-Rattennieren; in vitro verringerte es die Hochglukose-induzierte Podozytenapoptose und unterdrückte die Expression proinflammatorischer Zytokine in Podozyten, erreicht durch Hemmung der p38-MAPK/NF-κB-Aktivierung in Nierengewebe und Podozyten. Dies ist für den ASH-Bereich relevant, da es die antiinflammatorischen und nierenprotektiven Eigenschaften einer aus Blutegeln extrahierten Substanz in einem Krankheitsmodell untersucht. Allerdings stammen sämtliche Befunde aus einem DN-Rattenmodell und aus in-vitro-Zellstudien; es werden keine Humandaten zu Dosierung, Sicherheit oder Wirksamkeit vorgelegt.
Zitation
Hirudin protects against kidney damage in streptozotocin-induced diabetic nephropathy rats by inhibiting inflammation via P38 MAPK/NF-κB pathway.
Han J et al. · Drug design, development and therapy, 2020
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026